Toxicology – Cyclobenzaprine

Core Concept

Cyclobenzaprine is a centrally acting skeletal muscle relaxant with a tricyclic chemical structure closely related to amitriptyline. In overdose, its dominant effects are usually sedation and antimuscarinic toxicity, particularly drowsiness, sinus tachycardia, agitation, confusion, dry mucosae, mydriasis, and urinary retention.

A useful toxicologic sequence is:

Cyclobenzaprine → central sedation + muscarinic antagonism → drowsiness/confusion + tachycardia + dry skin/mouth + mydriasis + urinary retention

Severe poisoning can additionally produce coma, seizures, hypotension, respiratory depression, QRS widening, and ventricular dysrhythmias, but important modern poison-center series show that cyclobenzaprine is considerably less cardiotoxic than classic tricyclic antidepressants in most isolated overdoses.

The major bedside principle is:

Cyclobenzaprine looks chemically like a TCA, but most isolated overdoses behave primarily as sedative-antimuscarinic poisoning rather than classic severe TCA cardiotoxicity.

Nevertheless, an ECG is essential because the rare patient who develops QRS widening or ventricular dysrhythmia should be treated as having sodium-channel blockade.

Current Forms and Uses

Cyclobenzaprine is used as an adjunct to rest and physical therapy for short-term relief of muscle spasm associated with acute painful musculoskeletal conditions. It is not considered effective for spasticity caused by cerebral or spinal-cord disease. Current labeling recommends limiting treatment to approximately 2–3 weeks because evidence for prolonged use is inadequate.

Immediate-release tablets are currently available in strengths including 5 mg, 7.5 mg, and 10 mg. The usual adult immediate-release dose is:

5 mg orally three times daily

which may be increased to 7.5–10 mg three times daily according to response. The old statement that 10 mg three times daily is simply the “usual dose” therefore overstates current starting therapy.

Extended-release formulations are also available as 15-mg and 30-mg capsules, generally administered once daily.

Pharmacology

Cyclobenzaprine acts predominantly in the central nervous system, particularly at brainstem motor pathways, reducing tonic somatic motor activity. It does not act directly at the neuromuscular junction and is not a peripheral skeletal-muscle paralytic.

Its pharmacologic profile includes:

Central sedation + antimuscarinic activity + alpha-adrenergic effects + monoaminergic activity

These actions explain the mixture of somnolence, anticholinergic findings, sinus tachycardia, occasional hypotension, and serotonergic drug interactions.

Relationship to Tricyclic Antidepressants

Cyclobenzaprine is structurally related to amitriptyline and imipramine, and older toxicology texts therefore often approached overdose as if it were essentially TCA poisoning.

That comparison is useful—but incomplete.

Two large poison-center studies demonstrate an important difference. A multicenter review of 402 isolated cyclobenzaprine ingestions found no deaths, no seizures, and no life-threatening dysrhythmias; common effects were lethargy, sinus tachycardia, and agitation. Doses ranged up to 1000 mg.

A later review of 209 isolated acute overdoses similarly found no deaths, no wide-QRS cases, and no ventricular dysrhythmias attributable to cyclobenzaprine. Hypotension was uncommon.

Thus:

Do not assume that every cyclobenzaprine overdose will behave like amitriptyline.

However, rare severe cardiotoxic cases and fatalities have been reported, and current FDA labeling continues to regard QRS widening, dysrhythmia, severe hypotension, seizures, and cardiac arrest as possible critical manifestations.

Mechanism of Toxicity

The most common toxicity reflects central nervous system depression and muscarinic receptor antagonism.

Antimuscarinic effects produce:

Mydriasis + dry mouth + dry/flushed skin + tachycardia + decreased bowel motility + urinary retention + delirium

At very large concentrations, cyclobenzaprine may also interfere with cardiac sodium conduction in a TCA-like manner. Clinically significant sodium-channel blockade is uncommon in isolated poisoning but should be suspected when the ECG demonstrates QRS widening, terminal conduction abnormalities, ventricular dysrhythmia, or severe hypotension.

Pharmacokinetics

Cyclobenzaprine is relatively slowly eliminated. Current immediate-release labeling reports an effective half-life of approximately 18 hours, with a wide range of about 8–37 hours. It is highly protein bound and undergoes extensive hepatic metabolism, including metabolism through CYP3A4, CYP1A2, and to a lesser extent CYP2D6.

Repeated three-times-daily dosing results in accumulation, with steady state reached after several days. Plasma concentrations are higher in older adults and patients with hepatic impairment.

The long half-life helps explain why symptomatic patients may remain sedated or anticholinergic well beyond the initial emergency-department period.

Toxic Dose

There is no precisely defined toxic or fatal dose.

Older statements that “several hundred milligrams may cause death” are too simplistic. Fatal cases exist, but large isolated overdoses are often survivable with supportive care.

In the classic multicenter poison-center study, doses ranged from 5 to 1000 mg. No deaths occurred, and no patient developed life-threatening cardiovascular or neurologic toxicity. No effects requiring treatment beyond gastrointestinal decontamination were reported below 100 mg in that series.

This should not be converted into a rigid “safe dose” rule. Patient age, formulation, coingestants, cardiovascular disease, serotonergic drugs, and uncertainty in the reported amount all matter.

Therefore:

Dose helps with risk assessment, but the ECG and clinical syndrome determine management.

Risk Factors for Severe Toxicity

Risk is increased by large intentional ingestion, extended-release formulations, alcohol or sedative coingestion, serotonergic coingestants, advanced age, hepatic impairment, and underlying cardiac conduction disease.

Current labeling specifically recognizes higher cyclobenzaprine concentrations in elderly patients and patients with hepatic impairment.

Extended-release labeling advises against use in moderate-to-severe hepatic impairment and recommends caution regarding the drug’s anticholinergic and sedating properties.

Drug Interactions

Cyclobenzaprine potentiates the effects of alcohol, barbiturates, opioids, benzodiazepines, and other CNS depressants. Coingestion can convert an otherwise moderate cyclobenzaprine overdose into clinically important respiratory depression or coma.

An important modern addition is its interaction with serotonergic medications.

Serotonin Syndrome

Cyclobenzaprine has serotonergic pharmacology and has been associated with serotonin syndrome, particularly when combined with other serotonergic drugs.

Reported interacting agents include:

SSRIs, SNRIs, TCAs, tramadol, meperidine, bupropion, and MAO inhibitors, among others. Current labeling specifically warns about this potentially life-threatening interaction.

The clinical syndrome includes:

Agitation/confusion + diaphoresis + hyperthermia + autonomic instability + tremor + hyperreflexia + clonus ± rigidity

This differs from uncomplicated antimuscarinic delirium, in which the skin and mucosa are characteristically dry and clonus/hyperreflexia are not typical.

Monoamine Oxidase Inhibitors

Cyclobenzaprine is contraindicated during treatment with an MAO inhibitor and for 14 days after MAOI discontinuation. Hyperpyretic reactions, seizures, and deaths have been reported with cyclobenzaprine or closely related tricyclic drugs in this setting.

Therefore:

Cyclobenzaprine + MAOI is a major interaction, not merely additive sedation.

Clinical Features

The typical isolated overdose produces:

Drowsiness + sinus tachycardia ± antimuscarinic findings

Current labeling identifies drowsiness and tachycardia as the most common manifestations of overdose. Less frequent findings include tremor, agitation, ataxia, confusion, hallucinations, hypertension, vomiting, and coma. Rare severe manifestations include cardiac arrest, dysrhythmias, severe hypotension, seizures, and neuroleptic-malignant-syndrome-like presentations.

Central Nervous System

Sedation is common and may range from mild drowsiness to significant somnolence. Patients can also develop agitation, confusion, hallucinations, dysarthria, ataxia, or delirium.

This apparent mixture of sedation and agitation is typical of drugs with both central sedative and antimuscarinic activity.

Coma is unusual in uncomplicated moderate isolated overdose and should prompt careful consideration of:

opioids, ethanol, benzodiazepines, sedative-hypnotics, hypoglycemia, trauma, seizures, or another coingestant.

Antimuscarinic Syndrome

Characteristic findings include:

Mydriasis, blurred vision, dry mouth, warm/dry skin, sinus tachycardia, urinary retention, decreased bowel sounds, agitation, hallucinations, and delirium.

Severe ileus and urinary retention are possible but uncommon.

Hyperthermia can result when reduced sweating combines with severe agitation.

Cardiovascular Effects

Sinus tachycardia is by far the most frequent cardiovascular abnormality and usually reflects antimuscarinic activity.

Mild hypertension may occur. Hypotension is less frequent and can result from vasodilation, severe CNS depression, dehydration, or rare myocardial/conduction toxicity.

Life-threatening ventricular dysrhythmias are uncommon in isolated cyclobenzaprine overdose, which distinguishes it from classic TCA poisoning.

Nevertheless, current labeling considers changes in QRS width or axis clinically significant markers of severe toxicity.

Respiratory Toxicity

Respiratory depression can occur from severe CNS depression, particularly after large overdose or coingestion of alcohol, opioids, benzodiazepines, or other sedatives.

Patients with declining mental status require close airway assessment.

Respiratory failure in a presumed cyclobenzaprine overdose should trigger strong consideration of an opioid or other sedative coingestant.

Seizures

Seizures are rare after isolated cyclobenzaprine overdose. In one large series of 402 isolated ingestions, no seizures occurred; another poison-center study found reported seizure events were not attributable to cyclobenzaprine itself.

Nevertheless, seizures remain described in postmarketing overdose reports and are plausible in severe poisoning or mixed ingestion.

Treat seizures with benzodiazepines first-line.

Gastrointestinal Effects

Nausea and vomiting can occur. Antimuscarinic effects may slow gastrointestinal motility and produce constipation or ileus.

Delayed gastric emptying is theoretically relevant after very large ingestions, although routine prolonged gastrointestinal decontamination is not supported.

Genitourinary Effects

Urinary retention is a classic antimuscarinic effect and may require bladder assessment or temporary catheterization when severe.

Patients with prostatic obstruction or other baseline voiding problems may be more susceptible.

Rhabdomyolysis

Rhabdomyolysis is uncommon but may develop after prolonged agitation, seizures, hyperthermia, or prolonged immobilization.

Check CK, potassium, renal function, and urinalysis in patients with those risk factors.

Diagnosis

Diagnosis is primarily clinical and based on history, medication access, physical findings, and ECG.

A characteristic presentation is:

Cyclobenzaprine exposure → drowsiness/tachycardia → dry antimuscarinic findings ± delirium

Because overdose frequently occurs in deliberate self-poisoning, clinicians should actively search for coingestants.

Differential Diagnosis

Important toxicologic alternatives include:

Tricyclic antidepressants, diphenhydramine and other antihistamines, antipsychotics, ethanol, opioids, benzodiazepines, sedative-hypnotics, serotonin syndrome, and sympathomimetic poisoning.

TCA poisoning is particularly important because QRS widening and severe cardiotoxicity require immediate sodium bicarbonate treatment.

Serotonin syndrome can overlap with cyclobenzaprine toxicity but is suggested by clonus, hyperreflexia, diaphoresis, increased bowel activity, and serotonergic coexposure rather than a purely dry antimuscarinic syndrome.

Initial Assessment

Begin with airway, breathing, circulation, bedside glucose, temperature, neurologic examination, and a careful medication history.

In unexplained respiratory depression, naloxone should be given when opioid toxicity is plausible. Naloxone does not reverse cyclobenzaprine itself.

Routine “coma cocktail” administration of thiamine or glucose to every patient is obsolete; glucose should be measured and hypoglycemia treated when present, while thiamine is used when clinically indicated.

ECG

Obtain an ECG after a significant cyclobenzaprine overdose.

Current labeling identifies QRS abnormalities as important markers of severe toxicity.

Assess:

heart rate, rhythm, PR interval, QRS duration, QT/QTc, and evidence of sodium-channel blockade.

A normal ECG strongly reduces concern for major TCA-like cardiotoxicity but does not replace clinical observation.

QRS Widening

A QRS duration of approximately ≥100 ms is traditionally regarded as concerning in this setting, consistent with current product labeling.

However, the key concept is not the exact number in isolation:

Cyclobenzaprine overdose + new QRS widening, ventricular dysrhythmia, or conduction-related hypotension = treat for sodium-channel blockade.

Laboratory Testing

Asymptomatic low-risk patients generally do not require extensive laboratory testing.

In symptomatic or intentional overdose, useful studies include:

glucose, electrolytes, renal function, and an acetaminophen concentration when the ingestion history is uncertain.

Additional tests should be targeted to the clinical picture. CK is appropriate after seizures, prolonged agitation, hyperthermia, or prolonged unconsciousness.

Blood gas and lactate can help when severe hypotension, seizures, respiratory failure, or major conduction abnormalities are present.

Cyclobenzaprine Levels

Serum cyclobenzaprine concentrations do not guide acute management.

Current labeling specifically advises against using plasma drug levels to direct overdose care.

Clinical status and ECG findings are more useful.

Initial Treatment

Treatment is primarily supportive.

Provide airway support, oxygen when indicated, IV access, cardiac monitoring for significant exposures, treatment of agitation or seizures, management of hypotension, and correction of hyperthermia or metabolic abnormalities.

A poison center or medical toxicologist should be consulted for severe or unusual toxicity, especially QRS widening, dysrhythmia, seizures, refractory delirium, or significant extended-release overdose.

Airway Management

Patients with severe CNS depression should be positioned and monitored carefully for aspiration and hypoventilation.

Endotracheal intubation is appropriate for:

loss of airway reflexes, persistent hypoventilation, profound coma, recurrent seizures, or inability to manage secretions.

Current product labeling warns that severe CNS depression can deteriorate abruptly.

Activated Charcoal

A single dose of activated charcoal may be considered after a recent substantial ingestion if the airway is intact or protected.

Modern toxicology guidance does not recommend activated charcoal routinely for every poisoned patient. Its greatest potential benefit is during approximately the first hour after ingestion, and it is contraindicated when the airway is unprotected.

Because cyclobenzaprine has antimuscarinic effects that may delay gastric emptying, occasional later use might be considered after a very large ingestion in consultation with toxicology, but evidence for improved clinical outcomes is lacking.

Gastric Lavage

The current cyclobenzaprine package insert still contains old language recommending large-volume gastric lavage after overdose.

That recommendation is not consistent with modern general toxicology practice.

AACT/EAPCCT guidance concludes that gastric lavage should not be performed routinely, if at all, because evidence for clinical benefit is poor and complications can be serious.

Therefore:

Routine gastric lavage is obsolete for cyclobenzaprine overdose.

Only an extraordinary, immediately life-threatening ingestion presenting extremely early could justify considering it after expert toxicology consultation and airway protection.

Do Not Induce Vomiting

Ipecac or other induced emesis has no role.

Cyclobenzaprine can cause sedation abruptly, increasing aspiration risk.

Sodium Bicarbonate

Cyclobenzaprine ordinarily does not require sodium bicarbonate merely because it resembles a TCA.

However, if there is evidence of cardiac sodium-channel blockade—particularly:

QRS widening + ventricular dysrhythmia ± severe conduction-related hypotension

then treat with IV sodium bicarbonate.

A reasonable toxicology regimen is:

Sodium bicarbonate 1–2 mEq/kg IV bolus

repeated according to ECG and hemodynamic response, followed when necessary by an alkalinizing infusion.

Current labeling recommends alkalinization when dysrhythmia or QRS widening occurs and identifies a target blood pH around 7.45–7.55, while avoiding excessive alkalemia.

The therapeutic endpoint is improvement in QRS duration, rhythm, and blood pressure, not attainment of a bicarbonate concentration.

Dysrhythmias

Correct oxygenation, acidemia, and electrolyte abnormalities first.

Sodium bicarbonate is first-line when sodium-channel blockade is suspected.

If ventricular dysrhythmia persists despite adequate bicarbonate therapy, lidocaine can be considered after toxicology consultation.

The product label still mentions bretylium and phenytoin as possible therapies, but bretylium is essentially obsolete in contemporary practice, and phenytoin is not a preferred treatment for toxicologic sodium-channel cardiotoxicity or drug-induced seizures.

Avoid class IA and IC sodium-channel-blocking antiarrhythmics such as procainamide and flecainide because they may worsen conduction toxicity.

Hypotension

Give isotonic crystalloid when volume depletion is present.

If clinically important hypotension persists despite appropriate fluids:

Norepinephrine is a reasonable first-line vasopressor.

The historical dopamine-first strategy and routine Trendelenburg positioning are outdated.

Persistent hypotension associated with QRS widening should also prompt immediate sodium bicarbonate therapy because myocardial sodium-channel blockade may be contributing.

Agitation

Mild antimuscarinic agitation can often be managed with environmental control and observation.

For significant agitation, benzodiazepines are reasonable, particularly when the diagnosis is uncertain, seizures are a concern, or serotonin syndrome cannot be excluded.

Excessive benzodiazepine administration should be avoided because cyclobenzaprine already produces sedation and may increase the likelihood of respiratory compromise.

Physostigmine – Important Modern Nuance

The old chapter recommends physostigmine 1–2 mg IV diagnostically for cyclobenzaprine-associated anticholinergic syndrome.

That is too liberal.

Physostigmine can be highly effective for severe pure antimuscarinic delirium, and modern evidence suggests it is safer than its historical reputation when appropriately selected. However, significant adverse effects are more concerning in patients with QRS prolongation or exposure to drugs capable of sodium-channel blockade. A large literature review concluded that physostigmine should be avoided when the ECG demonstrates QRS prolongation.

Cyclobenzaprine is structurally TCA-like and has at least theoretical and label-recognized potential for sodium-channel toxicity.

Therefore:

Physostigmine is not routine treatment for cyclobenzaprine overdose.

It may be considered only for severe, clearly antimuscarinic delirium when:

• the ECG is reassuring,
• QRS is not widened,
• no important TCA or other sodium-channel blocker is suspected,
• there is no significant bradycardia or conduction disease,
• and a medical toxicologist or poison center supports its use.

Current cyclobenzaprine labeling itself recommends against physostigmine except in exceptional severe cases after consultation with a poison center.

Serotonin Syndrome Treatment

If serotonin syndrome develops, stop cyclobenzaprine and other serotonergic drugs.

Treatment is primarily:

sedation with benzodiazepines + IV fluids + active cooling for significant hyperthermia + management of autonomic instability.

Severe hyperthermia from muscle activity requires aggressive sedation and external cooling. Antipyretics do not treat the mechanism.

Cyproheptadine may be considered in persistent moderate-to-severe serotonin toxicity when enteral administration is possible, but supportive care remains the priority.

Seizure Treatment

Use benzodiazepines first-line.

Refractory seizures can be treated with additional GABAergic therapy such as phenobarbital or propofol according to severity.

Phenytoin is generally a poor choice for toxin-induced seizures and is not preferred despite its appearance in older cyclobenzaprine labeling.

Hyperthermia

Hyperthermia can arise from antimuscarinic impairment of sweating, agitation, seizures, or serotonin toxicity.

Treatment is:

sedation + removal of excess clothing + active external cooling + IV fluids as appropriate.

Severe hyperthermia requires rapid control because rhabdomyolysis, AKI, coagulopathy, and neurologic injury can develop.

Rhabdomyolysis

Treat with appropriate IV crystalloid and management of the precipitating cause, especially seizures, agitation, or hyperthermia.

Follow CK, potassium, creatinine, and urine output.

Routine bicarbonate alkalinization of the urine is not required solely because rhabdomyolysis is present.

Enhanced Elimination

Hemodialysis does not have a meaningful role in cyclobenzaprine clearance.

Cyclobenzaprine is highly protein bound, extensively distributed, and present at relatively low plasma concentrations. Current labeling states dialysis is probably of no value.

Hemoperfusion, forced diuresis, and urinary manipulation are likewise not established therapies.

Antidote

There is no specific antidote for cyclobenzaprine poisoning.

Physostigmine is an antidote to selected antimuscarinic delirium, not a specific cyclobenzaprine antidote and not a treatment for sodium-channel toxicity.

Monitoring

Symptomatic patients should receive serial neurologic examinations and appropriate respiratory monitoring.

Significant overdose warrants continuous ECG monitoring until:

mental status is improving, vital signs are stable, and there is no evolving conduction abnormality.

Repeat the ECG if tachycardia worsens, hypotension develops, seizures occur, or mental status deteriorates.

Observation Period

The older fixed 6-hour rule is useful only as a rough minimum for immediate-release exposures.

In the classic multicenter poison-center series, all patients with a known ingestion time who eventually became symptomatic did so within approximately 4 hours.

Thus, an asymptomatic patient after an uncomplicated immediate-release ingestion who has a normal ECG and remains completely well through an adequate observation interval—commonly around 6 hours—may often be medically cleared.

However, observation should be longer for:

extended-release formulations, very large or uncertain ingestions, significant coingestants, abnormal ECG, evolving anticholinergic findings, older adults, or hepatic impairment.

Admission

Hospital admission is appropriate for patients with:

persistent altered mental status, significant agitation, recurrent vomiting with aspiration risk, hypotension, seizures, respiratory depression, urinary retention requiring treatment, significant serotonin toxicity, or ECG abnormalities.

ICU-level care is appropriate for:

coma requiring ventilation, seizures, severe hyperthermia, QRS widening, ventricular dysrhythmia, severe hypotension, or multiorgan complications.

Discharge

A patient may be discharged when:

mental status has returned to baseline, vital signs are stable, the ECG is reassuring, ambulation is safe, oral intake is adequate, and no delayed toxicity is expected from the formulation or coingestants.

Intentional ingestion requires appropriate psychiatric and safety assessment after medical stabilization.

Prognosis

Most isolated cyclobenzaprine overdoses have a favorable prognosis with supportive care.

In the major multicenter study of 402 isolated exposures, no deaths occurred, no seizures were observed, and life-threatening dysrhythmias were absent even at reported doses up to 1000 mg.

The later Texas poison-center analysis similarly found no deaths, ventricular dysrhythmias, or wide-QRS cases among 209 isolated acute overdoses.

Fatal cyclobenzaprine overdoses have nevertheless been reported, including cases with substantial postmortem cyclobenzaprine concentrations.

Thus the correct interpretation is:

Severe cardiotoxicity is rare—not impossible.

Pregnancy

The old FDA Pregnancy Category B terminology is obsolete.

Current extended-release labeling states that available human case-report data have not identified an increased risk of major birth defects, miscarriage, or adverse maternal/fetal outcomes, although the human evidence remains limited. Animal studies have shown reduced pup weight and survival at sufficiently high maternal exposures.

In acute overdose, maternal stabilization takes priority. Hypoxia, hypotension, seizures, and hyperthermia pose greater immediate fetal risks than most necessary resuscitative treatments.

Breastfeeding

Modern lactation data are more reassuring than the older statement that milk transfer was unknown.

The 2026 LactMed review reports that cyclobenzaprine concentrations in breast milk appear to be very low, with an estimated relative infant dose of approximately 0.5% in two studied mothers. Breastfeeding generally does not need to be stopped solely because therapeutic cyclobenzaprine is required.

The infant should nevertheless be monitored for excessive drowsiness, feeding problems, adequate weight gain, and respiratory depression, especially in neonates, preterm infants, or when the mother also receives opioids or other sedatives.

These therapeutic data should not automatically be extrapolated to a mother with a major acute overdose.

Older Adults

Cyclobenzaprine deserves particular caution in older adults because of sedation, antimuscarinic effects, confusion, urinary retention, and fall risk.

Current pharmacokinetic data show substantially increased drug exposure in elderly individuals.

A relatively modest overdose may therefore cause disproportionate delirium or sedation in an older patient.

Hepatic Impairment

Because cyclobenzaprine is extensively hepatically metabolized, plasma concentrations rise in hepatic dysfunction. Immediate-release labeling recommends cautious low-dose use in mild impairment and states that use in moderate-to-severe hepatic impairment is not recommended because adequate data are lacking.

This can prolong toxicity after overdose.

Important Pitfalls

A major pitfall is assuming that cyclobenzaprine is simply “amitriptyline without the antidepressant indication.” Its structure is similar, but poison-center data show that life-threatening sodium-channel cardiotoxicity is substantially less common in isolated cyclobenzaprine overdose.

The opposite error is equally dangerous: because cardiotoxicity is uncommon, clinicians should not ignore the ECG. New QRS widening or ventricular dysrhythmia requires immediate sodium bicarbonate treatment.

Another pitfall is treating simple sinus tachycardia with antiarrhythmics. Most tachycardia reflects antimuscarinic activity and does not need rhythm-specific therapy.

Do not use physostigmine reflexively simply because the patient is delirious and dry. Cyclobenzaprine has potential sodium-channel effects, and physostigmine is best reserved for carefully selected patients with a reassuring ECG after toxicology consultation.

The package insert’s routine recommendation for gastric lavage is outdated. Modern AACT/EAPCCT guidance states that lavage should not be performed routinely, if at all.

Another important modern pitfall is missing serotonin syndrome. Agitation, hyperthermia, diaphoresis, clonus, and hyperreflexia in a patient taking cyclobenzaprine with an SSRI, SNRI, tramadol, MAOI, or another serotonergic drug should not simply be labeled anticholinergic delirium.

Profound respiratory depression should trigger a search for opioids, ethanol, benzodiazepines, or other sedative coingestants rather than being automatically attributed to cyclobenzaprine.

Finally, do not use a serum cyclobenzaprine concentration to guide treatment. Current labeling specifically advises that plasma drug levels should not determine overdose management.

High-Yield Toxicology Pearls

Cyclobenzaprine overdose most commonly causes drowsiness + sinus tachycardia + antimuscarinic findings.

Its structure resembles a TCA, but large poison-center studies show that isolated cyclobenzaprine overdose much less commonly produces seizures, wide-QRS dysrhythmia, or fatal cardiotoxicity than amitriptyline overdose.

Current immediate-release dosing usually starts at 5 mg three times daily, with escalation to 7.5–10 mg three times daily if needed. Extended-release formulations contain 15 or 30 mg once daily. Therapy is generally limited to 2–3 weeks.

The main toxidrome is:

Sedation + tachycardia + dry mouth/skin + mydriasis + urinary retention ± antimuscarinic delirium

Always obtain an ECG after a significant overdose.

If there is QRS widening, ventricular dysrhythmia, or conduction-related hypotension, treat with:

Sodium bicarbonate 1–2 mEq/kg IV

and repeat according to ECG and hemodynamic response.

Sinus tachycardia alone does not require sodium bicarbonate.

Seizures are rare but should be treated with benzodiazepines. Phenytoin is not preferred for toxin-induced seizures.

Routine gastric lavage is obsolete despite language that persists in some current package inserts. Activated charcoal is selective rather than routine, with greatest potential benefit after a recent substantial ingestion when the airway is safe.

There is no specific antidote.

Physostigmine can reverse severe pure antimuscarinic delirium, but in cyclobenzaprine poisoning it should be highly selective, with a reassuring ECG and toxicology consultation; avoid it when QRS prolongation or another sodium-channel blocker is suspected.

Cyclobenzaprine can contribute to serotonin syndrome, especially with SSRIs, SNRIs, TCAs, tramadol, or MAO inhibitors. MAOI use is contraindicated during cyclobenzaprine treatment and for 14 days after MAOI discontinuation.

Hemodialysis does not meaningfully enhance elimination.

Most toxicity becomes evident within several hours after an immediate-release ingestion; a classic poison-center series found all eventually symptomatic patients with known timing had developed symptoms within 4 hours. Extended-release preparations and large or mixed ingestions require longer observation.

The most important clinical distinction is:

Cyclobenzaprine overdose usually behaves like an antimuscarinic sedative—but if the QRS widens, treat the patient like sodium-channel-blocker poisoning.